2022.01.12
I-Mab today announced that the first patient had been dosed in its China phase 2 study of efineptakin alfa in combination with pembrolizumab in patients with advanced solid tumors.
2022.01.06
I-Mab today announced that the senior management team have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares on the open market for an aggregate amount of minimum US$3 million and up to US$20 million no later than February 28, 20...
2021.12.31
I-Mab today announced its participation in the following conferences in January 2022.
2021.12.27
I-Mab announced that the CDE of China’s NMPA has approved I-Mab’s IND submission for the initiation of a phase 2 trial in China for enoblituzumabin combination with pembrolizumab in patients with solid tumors, including non-small cell lung cancer, urothelial carcinoma, and other selected cancers.
2021.12.20
I-Mab today announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company.
2021.12.15
I-Mab today announced that the CDE of China NMPA has approved the IND submission for the initiation of a phase 1 clinical study of the bispecific antibody TJ-CD4B in patients with solid tumors.
2021.12.14
Positive clinical activity was observed in heavily pretreated patients who had progressed on prior Anti-CD20 therapies.
2021.12.08
I-Mab today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimer's disease.
2021.12.07
I-Mab today announced that the Board of Directors of the Company approved a motion to pursue the listing of the Company’s ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited.
2021.12.03
I-Mab today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab in combination with atezolizumab in patients with ovarian cancer and other selected advanced or metastatic solid tumors.